p53 Review Article

You have free access to this content

TP53 and gastric carcinoma: A review†

  1. C.M. Fenoglio-Preiser*,
  2. J. Wang,
  3. G.N. Stemmermann,
  4. A. Noffsinger

Article first published online: 24 FEB 2003

DOI: 10.1002/humu.10180

Issue

Human Mutation

Human Mutation

Special Issue: Focus on p53 and Cancer

Volume 21, Issue 3, pages 258–270, March 2003

Additional Information

How to Cite

Fenoglio-Preiser, C.M., Wang, J., Stemmermann, G.N. and Noffsinger, A. (2003), TP53 and gastric carcinoma: A review. Hum. Mutat., 21: 258–270. doi: 10.1002/humu.10180

Author Information

  1. Department of Pathology, College of Medicine, University of Cincinnati, Cincinnati, Ohio

*University of Cincinnati, Department of Pathology, P.O. Box 670529, Cincinnati, OH 45267-0529

  1. †

    For the p53 Special Issue

Publication History

  1. Issue published online: 24 FEB 2003
  2. Article first published online: 24 FEB 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (179K)

REFERENCES

  • Ashcroft M, Kubbutat MH, Vousden KH. 1999. Regulation of p53 function and stability by phosphorylation. Cell Biol 19:1751–1758.
  • Baas IO, Mulder IR, Offerhaus JA, Vogelstein B, Hamilton SR. 1994. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5–12.
    Direct Link:
  • Banks L, Matlashewski G, Crawford L. 1994. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159:529–534.
    Direct Link:
  • Blok P, Craanen ME, Dekker W, Offerhaus GJA, Tytgat GN. 1998. No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis. J Pathol 186:36–40.
    Direct Link:
  • Bodmer W, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF, Linnolia RI. 1992. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743–749.
  • Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, Yamao T, Kondo H, Shirao K, Shimada Y, Saito D, Hasebe T, Mukai K, Seki S, Saito H, Johnston PG. 1998. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 4:1469–1471.
  • Bosari S, Viale G. 1995. The clinical significance of p53 aberrations in human tumours. Virchows Arch 427:229–241.
  • Brito MJ, Williams GT, Thompson H, Filipe MU. 1994. Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa. Gut 35:1697–1700.
  • Cascinu S, Graziano F, Ferro ED, Staccioli MP, Lig M, Carnevali A, Muretto P, Catalano G. 1998. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 83:1917–1922.
    Direct Link:
  • Conde AR, Martins G, Saraiva C, Rueff J, Monteiro C. 1999. Association of p53 genomic instability with the glutathione S-transferase null genotype in gastric carcinoma in the Portuguese population. Mol Pathol 52:131–134.
  • Correa P. 1988. A human model of gastric carcinogenesis. Cancer Res 48:3554–3560.
  • Correa P, Shiao Y. 1994. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 54:1914s–1943s.
  • Craanen ME, Blok P, Dekker W, Offerhaus GJA, Tytgat GNJ. 1995. Chronology of p53 protein accumulation in gastric carcinogenesis. Gut 36:848–852.
  • Dameron KM, Volpert OV, Tainsky MA, Bouck N. 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582–1584.
  • Danesi DT, Spano M, Fabiano A, Altavista P, Pasqualetti P, Toscano MG, Antonini F, Catalano P, Mecozzi A, Picconi A, Daffina A, Cucchiara G. 2000. Flow cytometric DNA ploidy, p53, PCNA, and c-erbB-2 protein expression as predictors of survival in surgically resected gastric cancer patients. Cytometry 42:27–34.
    Direct Link:
  • Deguchi R, Takagi A, Kawata H, Inoko H, Miwa T. 1995. Association between CagA+ helicobacter pylori infection and p53, bax, and transforming growth factor-B-RII gene mutations in gastric cancer patients. Int J Cancer 91:481–485.
    Direct Link:
  • Diez M., Medrano MJ, Guitierrez A, Lopez A, Muguerza JM, Hernandez P, Lozano O, Noguerales F, Ruiz A, Granell J. 2000. p53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy. Anticancer Res 20:3939–3934.
  • Dockhorn-Dworniczak B, Poremba C, Dantcheva R, Stucker A, Brommelkamp E, Blasius S, Mellin W, Roessner A, Yandell, Bocker W. 1994. Rapid detection of loss of heterozygosity of chromosome 17p by polymerase chain reaction-based variable number of tandem repeat analysis and detection of single-stranded conformation polymorphism of intragenic 53 polymorphisms. Virchows Arch 424:337–342.
  • Dunn BE, Phadnis SH, Henderson J, Choi H. 1995. Induction of gastric dysplasia by H. felis in p53-deficient mice. Gut 37(Suppl 1):A40.
  • Feng CW, Wang LD, Jiao LH, Liu B, Zheng S, Xie XJ. 2002. Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features. BMC Cancer 2:8.
  • Fenoglio-Preiser C, Carneiro F, Correa P, Guilford P, Lambert R, Megraud F, Munoz N, Powell SM, Rugge M, Sasko M, Stolte M, Watanabe H. 2000. Gastric carcinoma. In: HamiltonSR, AaltonenLA, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press. p 41–54.
  • Flejou JF, Gratio V, Muzeau F, Hamelin R. 1999. p53 abnormalities in adenocarcinoma of the gastric cardia and antrum. Mol Pathol 52:263–268.
  • Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G. 1995. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 76:720–726.
    Direct Link:
  • Giaccia AJ, Kastan MB. 1998. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12:2973–2983.
  • Giatromanolaki A, Stathopoulos GP, Koukourakis MI, Rigatos S, Vrettou E, Kittas C, Fountzilas G, Sivridis E. 2001. Angiogenesis and apoptosis-related protein (p53, bcl-2, and bax) expression versus response of gastric adenocarcinomas to paclitaxel and carboplatin chemotherapy. Am J Clin Oncol 24:222–226.
  • Gleeson CM, Sloan JM, McManus DT, Maxwell P, Arthur K, McGuigan JA, Ritchie AJ, Russell SHE. 1998. Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. Br J Cancer 77:277–286.
  • Gomyo Y, Osaki M, Kaibara N, Ito H. 1996. Numerical aberration and point mutation of p53 gene in human gastric intestinal metaplasia and well-differentiated adenocarcinoma: analysis by fluorescence in situ hybridization (FISH) and PCR-SSCP. Int J Cancer 66:594–599.
    Direct Link:
  • Hao Y, Zhang J, Yi C, Qian W. 1997. Abnormal change of p53 gene in gastric and precancerous lesions and APC gene deletion in gastric carcinoma and near tissues. J Tongji Med Univ 17:75–78.
  • Hibi K, Mitomi H, Koizumi W, Tanabe S, Saigenji K, Okayasu I. 1997. Enhanced cellular proliferation and p53 accumulation in gastric mucosa chronically infected with Helicobacter pylori. Am J Clin Pathol 108:26–34.
  • Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991. p53 mutations in human cancers. Science 253:49–53.
  • Hong WS, Hong SI, Lee DS, Son Y. 1994. Effect of non-tumor cell contamination on detection of p53 gene mutations in human gastric cancer cells by polymerase chain reaction single-strand conformation polymorphism analysis. Korean J Intern Med 9:20–24.
  • Hongyo T, Buzard GS, Palli D, Weghorst CM, Amorosi A, Galli M, Caporaso NE, Fraumeni JF Jr, Rice JM. 1995. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res 55:2665–2672.
  • Hosaka N, Ichikawa T, Ishikwa T, Nagashima Y, Kunisaki C, Takahashi M, Moriwaki Y, Akiyama H, Yamaguchi S, Ota M, Ooki S, Ike H, Shimada H. 2001. Correlation of immunohistochemical p53 labeling index with inhibition rate in chemosensitivity test in gastric and colon cancer. Anticancer Res 21:229–236.
  • Ichiyoshi Y, Oiwa H, Tomisaki S, Sakaguchi Y, Ohno S, Maehara Y, Sugimachi K. 1997. Overexpression of p53 is associated with growth pattern and prognosis in advanced gastric cancer. Hepatogastroenterology 44:546–553.
  • Ikeguchi M, Saito H, Katano K, Gomyo Y, Tsujitani S, Maeta M, Kaibara N. 1997. Relationship between the long-term effects of intraperitoneal chemotherapy and the expression of p53 and p21 in patients with gastric carcinoma at stage IIIa and stage IIIb. Int Surg 82:170–174.
  • Ikeguchi M, Saito H, Katano K, Tsujitani S, Maeta M, Kaibara N. 1998. Expression of p53 and p21 are independent prognostic factors in patients with serosal invasion by gastric carcinoma. Dig Dis Sci 43:964–970.
  • Imatani A, Sasano H, Asaki S, Toyota T, Saito M, Masuda T, Nagura H. 1996. Analysis of p53 abnormalities in endoscopic gastric biopsies. Anticancer Res 16:2049–2056.
  • Ioachim E, Stefanou GD, Agnantis NJ. 1997. Expression of p53 protein in gastric cancer: an immunohistochemical study with correlation to proliferative activity. Anticancer Res 17:513–517.
  • Iwamatsu H, Nishikura K, Watanabe H, Ajioka Y, Hashidate H, Kashimura H, Asakura H. 2001. Heterogeneity of p53 mutational status in the superficial spreading type of early gastric carcinoma. Gastric Cancer 4:20–26.
  • Jiang H, Han P, Jiang Y, Liang X, Hu C, Yang D. 1997. The clinical significance of the immunohistochemical detection of p53 protein in endoscopic biopsy specimens. Chin Med J 110:202–205.
  • Joypaul V, Newman EL, Hopwood D, Grant A, Qureshi S, Lane DP, Cuschieri A. 1993. Expression of p53 protein in normal, dysplastic and malignant gastric mucosa: an immunohistochemical study. J Pathol 170:279–283.
    Direct Link:
  • Joypaul V, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, Lane DP, Cuschieri A. 1994. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 69:943–946.
  • Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, Sugimachi K. 1993. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 67:589–593.
  • Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304–6311.
  • Kaye PV, Radebold K, Isaacs S, Dent DM. 2000. The expression of p53 and p21 waf1/cip1 in gastric carcinoma: lack of inter-relationship or correlation with prognosis. Eur J Surg Oncol 26:39–43.
  • Kikuyama S, Inada T, Shimizu K, Miyakita M, Ogata Y. 2001. p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer. Anticancer Res 21:2149–2154.
  • Kim CJ, Kim WH, Kim CW, Lee JB, Lee CK, Kim YL. 1995. Detection of 17p loss in gastric carcinoma using polymerase chain reaction. Lab Invest 72:232–236.
  • Kim JH, Takahashi T, Chiba I, Park JG, Birrer MJ, Roh JK, De Lee H, Kim JP, Minna JD, Gazdar AF. 1991. Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Natl Cancer Inst 83:938–943.
  • Kim JH, Uhm HD, Gong SJ, Shin DH, Choi JH, Lee HR, Noh SH, Kim BS, Cho JY, Rha SY, Yoo NC, Roh JK, Min JS, Lee KS, Kim BS. 1997. Relationship between p53 overexpression and gastric cancer progression. Oncology 54:166–170.
  • Kim J-P, Oh S-T, Hwang T-S, Chi J-G. 1994. The prognostic significance of c-erbB-2 and p53 protein expressions in gastric carcinoma. J Korean Med Sci 9:248–253.
  • Kim K-M, Lee A, Chae H-S, Shim S-I. 1995. Expression of p53 and NDP-K/nm23 in gastric carcinomas. J Korean Med Sci 10:406–413.
  • Kim YH, Kim N-G, Lim JG, Park C, Kim H. 2001. Chromosomal alterations in paired gastric adenomas and carcinomas. Am J Pathol 158:655–662.
  • Kobayashi M, Kawashima A, Mai M, Ooi A. 1996. Analysis of chromosome 17p13 (p53 locus) alterations in gastric carcinoma cells by dual color fluorescence in situ hybridization. Am J Pathol 149:1575–1584.
  • Kubicka S, Claas C, Staab S, Kuhnel F, Zender L, Trautwein C, Wagner S, Rudolph KL, Manns M. 2002. p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. Dig Dis Sci 47:114–121.
  • Kutach LS, Bolshakov S, Ananthaswamy HN. 1999. Detection of mutations and polymorphisms in the p53 tumor suppressor gene by single-strand conformation polymorphism analysis. Electrophoresis 20:1204–1210.
    Direct Link:
  • Lauren P. 1965. The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at histological classification. Acta Pathol Microbiol Scand 64:31–49.
  • Lee W-J, Shun C-T, Hong R-L, Wu M-S, Chang K-J, Chen K-M. 1998. Overexpression of p53 predicts shorter survival in diffuse type gastric cancer. Br J Surg 85:1138–1142.
    Direct Link:
  • Leung WK, To K-F, Ng Y-P, Lee T-L, Lau JYW, Chan FKL, Ng EKW, Chung SCS, Sung JJY. 2001. Association between cyclo-oxygenase 2 overexpression and missense mutations in gastric cancer. Br J Cancer 84:335–339.
  • Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323–331.
  • Lim BH, Soong R, Grieu F, Robbins PD, House AK, Iacopetta BJ. 1996. p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int J Cancer 69:200–204.
    Direct Link:
  • Liu XP, Kawauchi S, Oga A, Suehiro Y, Tsushimi K, Tsushimi M, Sasaki K. 2001a. Combined examination of p27 (Kip1), p21 (Waf1/Cip1) and p53 expression allows precise estimation of prognosis in patients with gastric carcinoma. Histopathology 39:603–610.
    Direct Link:
  • Liu XP, Tsushimi K, Tsushimi M, Oga A, Kawauchi S, Furuya T, Sasaki K. 2001b. Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma. Pathol Int 51:440–444.
    Direct Link:
  • Liu XP, Tsushimi K, Tsushimi M, Oga A, Kawauchi S, Oga A, Furuya T, Sasaki K. 2001c. Expression of p21 (WAF1/CIP1) and p53 proteins in gastric carcinoma: its relationship with cell proliferation activity and prognosis. Cancer Lett 170:183–189.
  • Maeda K, Kang S-M, Onoda N, Ogawa M, Sawada T, Nakata B, Kato Y, Chung Y-S, Sowa M. 1998. Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. Oncology 55:594–599.
  • Maesawa C, Tamura G, Suzuki S, Ogasawara S, Sakata K, Kashiwaba M, Satodate R. 1995. The sequential accumulation of genetic alterations characteristic of the colorectal adenoma–carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J Pathol 176:249–258.
    Direct Link:
  • Mai UEH, Perez-Perez GI, Wahl LM, Wahl SM, Blaser MJ, Smith PD. 1988. Soluble surface proteins from Helicobacter pylori activate monocytes/macrophages by lipopolysaccharide-independent mechanisms. J Clin Invest 87:894–900.
  • Martin HM, Filipe M, Morris RW, Lane DP, Silvestre F. 1992. p53 expression and prognosis in gastric carcinoma. Int J Cancer 50:859–862.
    Direct Link:
  • Matozaki T, Sakomoto C, Matsuda K, Suzuki T, Konda Y, Nakano O, Wada K, Uchida T, Nishisaki H, Munehiko N, Kasuga M. 1992a. Missense mutations and a deletion of the p53 gene in human gastric cancer. Biochem Biophys Res Commun 182:215–223.
  • Matozaki T, Sakamoto C, Suzuki T, Matsuda K, Uchida T, Nakano O, Wada K, Nishisaki H, Konda Y, Nagao M, Kasuga M. 1992b. p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells. Cancer Res 52:4335–4341.
  • Matturri L, Cazzullo A, Colombo B, Giordano F, Guarino M, Pallotti F, Turconi P, Lavezzi AM. 1998. Prognostic significance of different biological markers (DNA index, PCNA index, apoptosis, p53, karyotype) in 126 adenocarcinoma gastric biopsies. Anticancer Res 18:2819–2826.
  • McCulloch P, Taggart T, Ochiai A, O'Dowd G, Nash J, Sasako M. 1997. c-erbB2 and p53 expression are not associated with stage progression of gastric cancer in Britain or Japan. Eur J Surg Oncol 23:304–309.
  • McKee PH, Hobbs C, Hall PA. 1993. Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathology 23:377–379.
    Direct Link:
  • Milner J, Medcalf EA. 1991. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65:765–774.
  • Miracco C, Spina D, Vindigni C. Filipe MI, Tosi P. 1995. Cell proliferation patterns and p53 expression in gastric dysplasia. Int J Cancer 62:149–154.
    Direct Link:
  • Monig SP, Eidt S, Zirbes TK, Stippel D, Baldus SE, Pichlmaier H. 1997. p53 expression in gastric cancer: clinicopathological correlation and prognostic significance. Dig Dis Sci 42:2463–2467.
  • Motojima K, Furui MD, Kohara N, Ito T, Kanematsu T. 1994. Expression of p53 protein in gastric carcinomas is not independently prognostic. Surgery 116:890–895.
  • Muller W, Borchard F. 1996. Prognostic significance of p53 expression in gastric cancer. J Pathol 178:255–258.
    Direct Link:
  • Murakami K, Fujioka T, Okimoto T, Mitsuishi Y, Oda T, Nishizono A, Nasu M. 1999. Analysis of p53 gene mutations in Helicobacter pylori-associated gastritis mucosa in endoscopic biopsy specimens. Scand J Gastroenterol 34:474–477.
  • Nakata B, Chung KH-YS, Ogawa M, Ogawa Y, Yanagawa K, Muguruma K, Inoue Y, Yamashita Y, Onoda N, Maeda K, Sawada T, Sowa M. 1998. p53 protein overexpression as a predictor of response to chemotherapy in gastric cancer. Surg Today 28:595–598.
  • Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannebaum SR. 1992. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA 89:3030–3034.
  • Ochiai A, Yamaguchi Y, Hirohashi S. 1996. p53 mutations in the non-neoplastic mucosa of the human stomach showing intestinal metaplasia. Int J Cancer 69:29–33.
    Direct Link:
  • Ogawa M, Onoda N, Maeda K, Kato Y, Nakata B, Kang SM, Sowa M, Hirakawa K. 2001. A combination analysis of p53 and p21 in gastric carcinoma as a strong indicator for prognosis. Int J Mol Med 7:479–483.
  • Polat A, Cinel L, Dusmez D, Aydin O, Egilmez R. 2002. Expression of cell-cycle related proteins in Helicobacter pylori gastritis and association with gastric carcinoma. Neoplasma 49:95–100.
  • Poremba C, Yandell DW, Huang Q, Little JB, Mellin W, Schmid KW, Bocker W, Dockhorn-Dworniczak B. 1995. Frequency and spectrum of p53 mutations in gastric cancer—a molecular genetic and immunohistochemical study. Virchows Arch 426:447–455.
  • Ranzani GN, Luinetti O, Padovan LS, Calistri D, Renault B, Burrel M, Amadori D, Fiocca R, Solcia E. 1995. p53 gene mutations and protein nuclear accumulation are early events in intestinal type cancer but late events in diffuse type. Cancer Epidemiol Biomarkers Prev 4:223–231.
  • Renault B, van den Broek M, Fodde R, Wijnen J, Pellegata NS, Amadori D, Khan PM, Ranzani GN. 1993. Base transitions are the most frequent genetic changes at p53 in gastric cancer. Cancer Res 53:2614–2617.
  • Renault B, Calistri D, Buonsanti G, Ranzani GN. 1996. Microsatellite instability and mutations of p53 and TGF-βRII genes in gastric cancer. Hum Genet 98:601–607.
  • Rhyu MG, Park W-S, Jung Y-J, Choi S-W, Meltzer SJ. 1994. Allelic deletions of MCC/APC and p53 are frequent late events in human gastric carcinogenesis. Gastroenterology 106:1584–1588.
  • Ricevuto E, Ficorella C, Fusco C, Cannita K, Tessitore A, Toniato E, Gabriele A, Frati L, Marchetti P, Gulino A, Martinotti S. 1996. Molecular diagnosis of p53 mutations in gastric carcinoma by touch preparation. Am J Pathol 148:405–413.
  • Roviello F, Marrelli D, Vindigni C, De Stefano A, Spina D, Pinto E. 1999. p53 accumulation is a prognostic factor in intestinal-type gastric carcinoma but not in diffuse type. Ann Surg Oncol 6:739–745.
  • Rugge M, Shaio Y-H, Correa P, Baffa R, DiMario F. 1992. Immunohistochemical evidence of p53 overexpression in gastric epithelial dysplasia. Cancer Epidemiol Biomarkers Prev 1:551–554.
  • Rugge M, Shiao, Y-H, Busatto G, Cassaro M, Strobbe C, Russo VM, Leo G, Parenti AR, Scapinelli A, Arslan P, Egarter-Vigl E. 2000. The p53 gene in patients under the age of 40 with gastric cancer: mutation rates are low, but are associated with a cardiac location. Mol Pathol 53:207–210.
  • Saegusa M, Takano Y, Kamata Y, Okayasu I. 1996. Bcl-2 expression and allelic loss of the p53 gene in gastric carcinomas. J Cancer Res Clin Oncol 122:427–432.
  • Sakaguchi T, Watanabe A, Sawada H, Yamada Y, Yamashita J, Matsuda M, Nakajima M, Miwa T, Hirao T. 1998. Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer 82:1238–1243.
    Direct Link:
  • Sakurai S, Sano T, Nakajima T. 1995. Clinicopathological and molecular biological studies of gastric adenomas with special reference to p53 abnormality. Pathol Int 45:51–57.
    Direct Link:
  • Sano T, Tsujino T, Yoshida K, Nakayama H, Haruma K, Ito H, Nakamura Y, Kajiyama G, Tahara E. 1991. Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas. Cancer Res 51:2926–2931.
  • Sasaki I, Yao T, Nawata H, Tsuneyoshi M. 1999. Minute gastric carcinoma of differentiated type with special reference to the significance of intestinal metaplasia, proliferative zone and p53 protein during tumor development. Cancer 85:1719–1729.
    Direct Link:
  • Satoh K, Kihira K, Kawata H, Tokumaru K, Kumakura Y, Ishino Y, Kawakami S, Inoue K, Kojima T, Satoh Y, Mutoh H, Sugano K. 2001. p53 expression in the gastric mucosa before and after eradication of Helicobacter pylori. Helicobacter 6:31–36.
    Direct Link:
  • Schneider BG, Hilsenbeck SG, Hensel CH, Pekkel V, Shelton CH, Rodriquez-Martinez HA, Guitierrez-Diaz ME, Pulitzer DR, Allred DC. 1994. p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos. Virchows Arch 424:187–193.
  • Semba S, Yokozaki H, Yamamoto S, Yasui W, Tahara E. 1996. Microsatellite instability in precancerous lesions and adenocarcinomas of the stomach. Cancer 77:1620–1627.
  • Seruca R, David L, Castedo S, Veiga I, Borresen A-L, Sobrinho-Simoes M. 1994. p53 alterations in gastric carcinoma: a study of 56 primary tumors and 204 nodal metastases. Cancer Genet Cytogenet 75:45–50.
  • Setala L, Kosma V-M, Lipponen P, Naukkarinen A, Nordling S, Hollmen S, Eskelinen M. Syrjanen, K, Alhava E. 1998. Clinical relevance of p53 index and expression of proliferating cell nuclear antigen and Ki-67 in gastric cancer. J Cancer Res Clin Oncol 124:497–502.
  • Shaulsky G, Goldfinger N, Tosky MS, Levine AJ, Rotter V. 1991. Nuclear localization is essential for the activity of the p53 protein. Oncogene 6:2055–2065.
  • Sheffield VC, Beck JS, Kwiteck AE, Sandstrom DW, Stone EM. 1993. The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitution. Genomics 16:325–332.
  • Shepherd T, Tolbert D, Benedetti J, MacDonald J, Stemmermann G, Wiest J, DeVoe G, Miller MA, Wang J, Noffsinger A, Fenoglio-Preiser CM. 2000. Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology 118:1039–1044.
  • Shiao Y-H, Rugge M, Correa P, Lehmann HP, Scheer WD. 1994. p53 alteration in gastric precancerous lesions. Am J Pathol 144:511–517.
  • Shiao Y-H, Palli D, Buzard GS, Caporaso NE, Amorosi A, Saieva C, Fraumeni JF, Jr, Anderson LM, Rice JM. 1998. Implications of p53 mutation spectrum for cancer etiology in gastric cancers of various histologic types from a high-risk area of central Italy. Carcinogenesis 19:2145–2149.
  • Shiao Y-H, Palli D, Caporaso NE, Alvord WG, Amorosi A, Nesi G, Saieva C, Masala G, Fraumeni JF, Jr, Rice JM. 2000. Genetic and immunohistochemical analyses of p53 independently predict regional metastasis of gastric cancers. Cancer Epidemiol Biomarkers Prev 9:631–633.
  • Shibata A, Parsonnet J, Longacre TA, Garcia MI, Puligandla B, Davis RE, Vogelman JH, Orentreich N, Habel LA. 2002. CagA status of Helicobacter pylori infection and p53 mutations in gastric adenocarcinoma. Carcinogenesis 23:419–424.
  • Shun C-T, Wu M-S, Lin J-T, Chen S-Y, Wang H-P, Lee W-J, Wang T-H, Chuang S-M. 1997. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Hepatogastroenterology 44:604–609.
  • Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House AK, Iacopetta BJ. 1996. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 27:1050–1055.
  • Starzynska T, Bromley M, Ghosh A, Stern PL. 1992. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 66:558–562.
  • Starzynska T, Markiewski M, Domagala W, Marlicz J, Mietkiewski J, Roberts SA. Stern PL. 1996. The clinical significance of p53 accumulation in gastric carcinoma. Cancer 77:2005–2012.
    Direct Link:
  • Stemmermann G, Heffelfinger SC, Noffsinger A, Hui YZ, Miller MA, Fenoglio-Preiser CM. 1994. The molecular biology of esophageal and gastric cancer and their precursors: oncogenes, tumor suppressor genes, and growth factors. Hum Pathol 25:968–981.
  • Strickler JG, Zheng J, Shu Q, Burgart LJ, Alberts SR, Shibata D. 1994. p53 and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res 54:4750–4755.
  • Sud R, Wells D, Talbot IC, Delhanty JDA. 2001. Genetic alterations in gastric cancers from British patients. Cancer Genet Cytogenet 126:111–119.
  • Sugai T, Habano W, Nakamura S, Yoshida T, Uesugi N, Suto T, Itoh C. 1998. Correlation of histologic morphology and tumor stage with molecular genetic analysis using microdissection in gastric carcinomas. Diag Mol Pathol 7:235–240.
  • Sugimura T, Kawaki T. 1973. Experimental stomach cancer. Methods Cancer Res 7:245–308.
  • Tahara E, Semba S, Tahara H. 1996. Molecular biological observations in gastric cancer. Semin Oncol 23:307–315.
  • Tamura G, Kihana T, Nomura K, Terada M, Sugimura T, Hirohashi S. 1991. Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation analysis. Cancer Res 51:3056–3058.
  • Tamura G, Sakata K, Nishizuka S, Maesawa C, Suzuki Y, Terashima M, Eda Y, Satodate R. 1996. Allelotype of adenoma and differentiated adenocarcinoma of the stomach. J Pathol 180:371–377.
    Direct Link:
  • Tang H, Hokita S, Che X, Baba M, Aridome K, Kijima F, Tanabe G, Takao S, Aikou T. 1997. Comparison of p53 expression in proximal and distal gastric cancer: histopathologic correlation and prognostic significance. Ann Surg Oncol 4:470–474.
  • Taniere P, Martel-Planche G, Maurici D, Lombard-Bohas C, Scoazec J-Y, Montesano R, Berger F, Hainaut P. 2001. Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia. Am J Pathol 158:33–40.
  • Tohdo H, Yokozaki H, Haruma K, Kajiyama G, Tahara E. 1993. p53 gene mutations in gastric adenomas. Virchows Arch B Cell Pathol Incl Mol Pathol 63:191–195.
  • Tolbert D, Fenoglio-Preiser CM, Noffsinger, DeVoe G, MacDonald J, Benedetti J, Stemmermann GN. 1999a. The relation of p53 gene mutations to gastric cancer subsite and phenotype. Cancer Causes Control 10:227–231.
  • Tolbert DM, Noffsinger AE, Miller MA, DeVoe GW, Stemmermann GN, MacDonald JS, Fenoglio-Preiser CM. 1999b. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status. Mod Pathol 12:54–60.
  • Uchino S, Noguchi M, Hirota T, Itabashi M, Saito T, Kobayashi M, Hirohashi S. 1992. High incidence of nuclear accumulation of p53 protein in gastric cancer. Jpn J Clin Oncol 22:225–231.
  • Victorzon M, Nordling S, Haglund C, Lundin J, Roberts PJ. 1996. Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur J Cancer 32A:215–220.
  • Vjtesek B, Bartek J, Midgley CA, Lane DP. 1992. An immunohistochemical analysis of human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237–244.
  • Wang J-Y, Lin S-R, Hsieh J-S, Hsu C-H, Huang Y-S, Huang T-J. 2001. Mutations of the p53 gene in gastric carcinoma in Taiwan. Anticancer Res 21:513–520.
  • Wang LD, Shi, ST, Zhou, Goldstein S, Hong J-Y, Shao P, Qui S-L, Yang SY. 1994. Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int J Cancer 59:514–519.
    Direct Link:
  • Wink DA, Kasprzak KS, Maragos CM, Elespuru RK, Misra M, Dunams TM, Cebula TA, Koch WH, Andrews AW, Allen JS. 1992. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 254:1001–1003.
  • Wu M-S, Shun C-T, Wang H-P, Sheu J-C, Lee W-J, Wang J-T, Wang T-H, Lin J-T. 1997. Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology 112:1457–1465.
  • Wu M-S, Shun C-T, Lee W-C, Chen C-J, Wang H-P, Lee W-J, Sheu J-C, Lin J-T. 1998a. Overexpression of p53 in different subtypes of intestinal metaplasia and gastric cancer. Br J Cancer 78:971–973.
  • Wu M-S, Shun C-T, Sheu J-C, Wang H-P, Wang J-T, Lee W-J, Chen C-J, Wang T-H, Lin J-T. 1998b. Overexpression of mutant p53 and c-erbB-2 proteins and mutations of the p15 and p16 genes in human gastric carcinoma: with respect to histological subtypes and stages. J Gastroenterol Hepatol 13:305–310.
    Direct Link:
  • Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, Kuroshima K, Aikou T. 1999. Cooccurence of reduced expression of α-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer. Oncology 57:131–137.
  • Yamada Y, Yoshida T, Hayashi K, Sekiya T, Yokata J, Hirohashi S, Nakatani K, Nakano H, Sugimura T, Terada M. 1991. p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. Cancer Res 51:5800–5805.
  • Yasui W, Akama Y, Kuniyasu H, Yokozaki H, Semba S, Shimamoto F, Tahara E. 1996a. Expression of cyclin-dependent kinase inhibitor p21 waf 1/cip1 in nonneoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol 180:122–128.
    Direct Link:
  • Yasui W, Akama Y, Kuniyasu H, Yokozaki H, Semba S, Shimamoto F, Tahara E. 1996b. Expression of cyclin E in human gastric adenomas and adenocarcinomas: correlation with proliferative activity and p53 status. J Exp Ther Oncol 1:88–94.
  • Yeh K-H, Shun C-T, Chen C-L, Lin J-T, Lee W-J, Lee P-H, Chen Y-C, Cheng A-L. 1999. Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy. Hepatogastroenterology 46:610–615.
  • Yustein AS, Harper JC, Petroni GR, Cummings OW, Moskaluk CA, Powell SM. 1999. Allelotype of gastric adenocarcinoma. Cancer Res 59:1437–1441.
  • Zhang Z, Yuan Y, Gao H, Dong M, Wang L, Gong Y-H. 2001. Apoptosis, proliferation and p53 gene expression of H. pylori associated gastric epithelial lesions. World J Gastroenterol 7:779–782.
Get PDF (179K)